NAD+ Consuming Enzymes: Involvement in Therapies and Prevention of Human Diseases-Reference-Cited by-同舟云学术

NAD+ Consuming Enzymes: Involvement in Therapies and Prevention of Human Diseases

Published:2023-07-10 Issue:12 Volume:23 Page:1351-1354
ISSN:1871-5206
Container-title:Anti-Cancer Agents in Medicinal Chemistry
language:en
Short-container-title:ACAMC

Author:

Masutani Mitsuko¹^ORCID,Miwa Masanao²^ORCID,Poltronieri Palmiro³^ORCID

Affiliation:

1. Department of Molecular and Genomic Biomedicine, Graduate School of Biomedical Sciences, Center for Bioinformatics and Molecular Medicine, Nagasaki, Japan

2. Nagahama Institute of Bio-Science and Technology, Nagahama, Japan

3. Institute of Sciences of Food Productions (ISPA-CNR), National Research Council of Italy, Lecce, Italy

Abstract

Abstract: Neuroprotection is one of the hot topics in medicine. Alzheimer’s disease, amyotrophic lateral sclerosis, retinal pigment epithelial (RPE) degeneration, and axonal degeneration have been studied for the involvement of NAD depletion. Localized NAD+ depletion could lead to overactivation and crowding of local NAD+ salvage pathways. It has been stated that NAD+ depletion caused by PARPs and PAR cycling has been related to metabolic diseases and cancer. Additionally, it is now acknowledged that SARM1 dependent NAD+ depletion causes axon degeneration. New targeted therapeutics, such as SARM1 inhibitors, and NAD+ salvage drugs will help alleviate the dysfunctions affecting cell life and death in neurodegeneration as well as in metabolic diseases and cancer.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference16 articles.

1. Poltronieri P.; Miwa M.; Masutani M.; ADP-ribosylation as posttranslational modification of proteins: Use of inhibitors in cancer control. Int J Mol Sci 2021,22(19),10829

2. Antolín A.A.; Mestres J.; Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget 2014,5(10),3023-3028

3. Sandhu D.; Antolin A.A.; Cox A.R.; Jones A.M.; Identification of different side effects between PARP inhibitors and their polypharmacological multitarget rationale. Br J Clin Pharmacol 2022,88(2),742-752

4. Palve V.; Knezevic C.E.; Bejan D.S.; Luo Y.; Li X.; Novakova S.; Welsh E.A.; Fang B.; Kinose F.; Haura E.B.; Monteiro A.N.; Koomen J.M.; Cohen M.S.; Lawrence H.R.; Rix U.; The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol 2022,29(2),202-214

5. Figley M.D.; Gu W.; Nanson J.D.; Shi Y.; Sasaki Y.; Cunnea K.; Malde A.K.; Jia X.; Luo Z.; Saikot F.K.; Mosaiab T.; Masic V.; Holt S.; Hartley-Tassell L.; McGuinness H.Y.; Manik M.K.; Bosanac T.; Landsberg M.J.; Kerry P.S.; Mobli M.; Hughes R.O.; Milbrandt J.; Kobe B.; DiAntonio A.; Ve T.; SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron 2021,109(7),1118-1136

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD+ depletion;Cell Reports;2024-05